Kim Gi Jeong, Kim Dong-Hoon, Min Kyueng-Whan, Kim Young Hwan, Oh Young Ha
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Pathol Res Pract. 2018 Apr;214(4):565-571. doi: 10.1016/j.prp.2018.02.004. Epub 2018 Feb 14.
Decreased expression of p27 and p57 is considered as a prognostic indicator in patients with breast cancer receiving adjuvant chemotherapy. Previous in vitro studies have reported that reduced expression of p27 and p57 is associated with resistance to taxane, which is one of the most effective chemotherapeutic agents. In this study, we investigated the association of low p27 and p57 expression with outcomes in patients with breast cancer.
We investigated 226 cases of breast cancer from Kangbuk SMC between 2000 and 2005. Levels of p27 and p57 expression were evaluated using immunohistochemical staining of tumor tissue microarray specimens. The relationships between the expression levels of the markers and patients' outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard model.
Low p57 expression was only associated with negative progesterone receptor status (p = 0.034), whereas p27 expression was associated with poor prognosis of patients receiving adjuvant chemotherapy (p = 0.005). More detailed analysis revealed that low p27 expression affects the overall survival rate of patients receiving adjuvant chemotherapy including taxane (p = 0.026), but not that of patients receiving chemotherapy without taxane.
Low p27 expression may be useful to predict overall survival in patients with breast cancer who are treated with taxane. Evaluation of p27 expression may provide further prognostic information beyond traditional prognostic biomarkers and an understanding of the mechanisms that impart resistance against chemotherapy.
p27和p57表达降低被认为是接受辅助化疗的乳腺癌患者的预后指标。以往的体外研究报道，p27和p57表达降低与对紫杉烷耐药有关，紫杉烷是最有效的化疗药物之一。在本研究中，我们调查了p27和p57低表达与乳腺癌患者预后的相关性。
我们调查了2000年至2005年间江北三星医院的226例乳腺癌病例。使用肿瘤组织微阵列标本的免疫组织化学染色评估p27和p57的表达水平。采用Kaplan-Meier法和Cox比例风险模型分析标志物表达水平与患者预后的关系。
p57低表达仅与孕激素受体阴性状态相关（p = 0.034），而p27表达与接受辅助化疗患者的不良预后相关（p = 0.005）。更详细的分析显示，p27低表达影响接受包括紫杉烷在内的辅助化疗患者的总生存率（p = 0.026），但不影响未接受紫杉烷化疗患者的总生存率。
p27低表达可能有助于预测接受紫杉烷治疗的乳腺癌患者的总生存率。评估p27表达可能提供超越传统预后生物标志物的进一步预后信息，并有助于理解赋予化疗耐药性的机制。
